UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The Economic Value Of An Innovative Knee Implant System For Total Knee Arthroplasty

Value in health, 2013-05, Vol.16 (3), p.A225-A225

2013

Volltextzugriff (PDF)

PMS40 - The Economic Value Of An Innovative Knee Implant System For Total Knee Arthroplasty

Value in health, 2013-05, Vol.16 (3), p.A225-A225

2013

Volltextzugriff (PDF)

Clinical and functional status over the first three months of treatment: Results from the schizophrenia outpatient health outcomes (SOHO) study

Schizophrenia research, 2003-03, Vol.60 (1), p.282-282

2003

Volltextzugriff (PDF)

P.2.143 Extrapyramidal symptoms after six months of treatment: Results from the schizophrenia outpatient health outcomes (SOHO) study

European neuropsychopharmacology, 2003-10, Vol.13, p.S341-S342

2003

Volltextzugriff (PDF)

Functional outcomes in schizophrenia: A European comparison of olanzapine and haloperidol

Schizophrenia research, 2000, Vol.41 (1), p.189-189

2000

Volltextzugriff (PDF)

The treatment of schizophrenia across Europe: Between country baseline differences in the schizophrenia outpatient health outcomes (SOHO) study

European neuropsychopharmacology, 2002-10, Vol.12, p.317-317

2002

Volltextzugriff (PDF)

Hospitalization rates associated with olanzapine, risperidone, and haloperidol treatment in patients with schizophrenia: Results from a U.S. randomized controlled trial

European neuropsychopharmacology, 2002-10, Vol.12, p.315-315

2002

Volltextzugriff (PDF)

Statistical models for population heterogeneity in epidemiological longitudinal studies: Person centred latent class analysis to identify casemix groups in the schizophrenia outpatient health outcomes study

European neuropsychopharmacology, 2002-10, Vol.12, p.314-314

2002

Volltextzugriff (PDF)

Gender differences in schizophrenia: Results from the schizophrenia outpatient health outcomes study (SOHO)

Schizophrenia research, 2003-03, Vol.60 (1), p.285-285

2003

Volltextzugriff (PDF)

Economic aspects of bipolar disorder in Europe

European psychiatry, 2002-05, Vol.17, p.151-151

2002

Volltextzugriff (PDF)

Schizophrenia treatment in Europe: country differences in the SOHO Study

European psychiatry, 2002-05, Vol.17, p.150-150

2002

Volltextzugriff (PDF)

Baseline results from SOHO: a pan-European, observational study

European psychiatry, 2002-05, Vol.17, p.150-151

2002

Volltextzugriff (PDF)

Olanzapine or risperidone treatment initiation: SOHO Study Results

European psychiatry, 2002-05, Vol.17, p.150-150

2002

Volltextzugriff (PDF)

Functional outcomes in schizophrenia: A European comparison of olanzapine and haloperidol

European neuropsychopharmacology, 1999-09, Vol.9, p.289-289

1999

Volltextzugriff (PDF)

Apples and apples, apples and oranges: The use and abuse of average daily dose in comparisons of atypical antipsychotic drug acquisition costs

Schizophrenia research, 2000, Vol.41 (1), p.214-215

2000

Volltextzugriff (PDF)

Gender differences in schizophrenia: Results from the schizophrenia outpatient health outcomes study (SOHO)

European neuropsychopharmacology, 2002-10, Vol.12, p.293-293

2002

Volltextzugriff (PDF)

Olanzapine versus haloperidol as initial treatment in acute mania: Prospective comparison of work functional outcomes

European neuropsychopharmacology, 2002-10, Vol.12, p.307-307

2002

Volltextzugriff (PDF)

Frequency and hospitalisation-related costs of manic episodes in patients with bipolar I disorder in France

European psychiatry, 2002-05, Vol.17, p.108-108

2002

Volltextzugriff (PDF)

Apples and apples, apples and oranges: The use and abuse of average dally dose in comparisons of atypical antipsychotic drug acquisition costs

European neuropsychopharmacology, 1999-09, Vol.9, p.291-291

1999

Volltextzugriff (PDF)

Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: Results from a randomized clinical trial

European neuropsychopharmacology, 1998-11, Vol.8, p.S236-S236

1998

Volltextzugriff (PDF)

Resource use and quality of life of olanzapine compared with risperidone; Results from an international randomized clinical trial

European neuropsychopharmacology, 1998-11, Vol.8, p.S225-S226

1998

Volltextzugriff (PDF)

P02.317 Olanzapine versus risperidone: A prospective comparison of clinical and economic outcomes in schizophrenia

European psychiatry, 2000-10, Vol.15 (S2), p.s408-s408

2000

Volltextzugriff (PDF)

Intent-to-treat analysis of repeated measures data from a randomized clinical trial comparing the cost and effectiveness of treatment for schizophrenia with olanzapine or haloperidol

European neuropsychopharmacology, 1998-11, Vol.8, p.S235-S235

1998

Volltextzugriff (PDF)

A cost effectiveness clinical decision analysis for schizophrenia: Results across four countries

European neuropsychopharmacology, 1998-11, Vol.8, p.S236-S236

1998

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Aktive Filter

ThemaBenzodiazepines

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(18)

Publikationsform

Artikel
(24)

Sprache

Englisch
(24)

Erscheinungsjahr

n.n

Thema

Internal Medicine
(1)

Kollektion

1 weiteren anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Menü

Weitere Dienste

Einstellungen

The Economic Value Of An Innovative Knee Implant System For Total Knee Arthroplasty

PMS40 - The Economic Value Of An Innovative Knee Implant System For Total Knee Arthroplasty

Clinical and functional status over the first three months of treatment: Results from the schizophrenia outpatient health outcomes (SOHO) study

P.2.143 Extrapyramidal symptoms after six months of treatment: Results from the schizophrenia outpatient health outcomes (SOHO) study

Functional outcomes in schizophrenia: A European comparison of olanzapine and haloperidol

The treatment of schizophrenia across Europe: Between country baseline differences in the schizophrenia outpatient health outcomes (SOHO) study

Hospitalization rates associated with olanzapine, risperidone, and haloperidol treatment in patients with schizophrenia: Results from a U.S. randomized controlled trial

Statistical models for population heterogeneity in epidemiological longitudinal studies: Person centred latent class analysis to identify casemix groups in the schizophrenia outpatient health outcomes study

Gender differences in schizophrenia: Results from the schizophrenia outpatient health outcomes study (SOHO)

Economic aspects of bipolar disorder in Europe

Schizophrenia treatment in Europe: country differences in the SOHO Study

Baseline results from SOHO: a pan-European, observational study

Olanzapine or risperidone treatment initiation: SOHO Study Results

Functional outcomes in schizophrenia: A European comparison of olanzapine and haloperidol

Apples and apples, apples and oranges: The use and abuse of average daily dose in comparisons of atypical antipsychotic drug acquisition costs

Gender differences in schizophrenia: Results from the schizophrenia outpatient health outcomes study (SOHO)

Olanzapine versus haloperidol as initial treatment in acute mania: Prospective comparison of work functional outcomes

Frequency and hospitalisation-related costs of manic episodes in patients with bipolar I disorder in France

Apples and apples, apples and oranges: The use and abuse of average dally dose in comparisons of atypical antipsychotic drug acquisition costs

Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: Results from a randomized clinical trial

Resource use and quality of life of olanzapine compared with risperidone; Results from an international randomized clinical trial

P02.317 Olanzapine versus risperidone: A prospective comparison of clinical and economic outcomes in schizophrenia

Intent-to-treat analysis of repeated measures data from a randomized clinical trial comparing the cost and effectiveness of treatment for schizophrenia with olanzapine or haloperidol

A cost effectiveness clinical decision analysis for schizophrenia: Results across four countries

Aktive Filter

Suchergebnisse filtern